TRDA News and Press, Entrada Therapeutics Inc. From 11/22/23

2023-11-22 12:41:46 ET More on Mid-day movers stock. BioVie: Upcoming Phase 3 Readout In Alzheimer's May Create Significant Value BioVie: Bullish Signals From Blinded Data Presentation (Rating Upgrade) BioVie: Well-Powered Phase 3 Trial In Alzheimer's Could Greatly B...

2023-11-22 08:26:36 ET More on Entrada Seeking Alpha’s Quant Rating on Entrada Therapeutics Historical earnings data for Entrada Therapeutics Financial information for Entrada Therapeutics For further details see: Entrada says FDA declined to lift ...

– Company completes dosing of first and second cohorts in Phase 1 clinical trial, ENTR-601-44-101 – – ENTR-601-44 clinical development program remains on track with data readout expected in second half of 2024 – – U.S. FDA clinical hold on ...

2023-11-07 08:37:21 ET More on Entrada Therapeutics Seeking Alpha’s Quant Rating on Entrada Therapeutics Historical earnings data for Entrada Therapeutics Financial information for Entrada Therapeutics For further details see: Entrada Therapeutics ...

– Initiated a Phase 1 clinical trial of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy, marking Entrada’s transition to a clinical-stage company – – Expanded the Company’s Duchenne franchise with the selection of...

CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...

Entrada Therapeutics Inc. (TRDA) is expected to report $-0.55 for Q3 2023

– Initiation of Phase 1 clinical trial marks Entrada’s transition into a clinical company – – Data anticipated in the second half of 2024 – BOSTON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmac...

- In its inaugural year, DREAMS Grant Program awards $25,000 each to three U.S.-based non-profit organizations working to combat disparity and support people living with Duchenne - - Announced in conjunction with World Duchenne Awareness Day, awards are designed to uplift programs that ...

BOSTON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the Company...